News
NCNA
1.440
-2.04%
-0.030
Weekly Report: what happened at NCNA last week (0803-0807)?
Weekly Report · 21h ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at NCNA last week (0727-0731)?
Weekly Report · 08/03 09:52
Weekly Report: what happened at NCNA last week (0720-0724)?
Weekly Report · 07/27 09:55
Weekly Report: what happened at NCNA last week (0713-0717)?
Weekly Report · 07/20 09:52
Weekly Report: what happened at NCNA last week (0706-0710)?
Weekly Report · 07/13 09:54
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/10 17:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 07/10 12:05
Weekly Report: what happened at NCNA last week (0629-0703)?
Weekly Report · 07/06 09:56
Weekly Report: what happened at NCNA last week (0622-0626)?
Weekly Report · 06/29 09:53
Weekly Report: what happened at NCNA last week (0615-0619)?
Weekly Report · 06/22 09:59
Weekly Report: what happened at NCNA last week (0608-0612)?
Weekly Report · 06/15 10:00
NuCana Shareholders Approve All Resolutions at June 2026 AGM
TipRanks · 06/08 12:15
Weekly Report: what happened at NCNA last week (0601-0605)?
Weekly Report · 06/08 09:57
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 06/04 21:05
NuCana appoints Ian Webster as CFO
TipRanks · 06/01 12:43
NuCana Confirms Ian Webster as CFO to Steer Oncology Pipeline Through Key 2026 Milestones
TipRanks · 06/01 12:31
NuCana Appoints Ian Webster CFO, Effective Immediately
Benzinga · 06/01 12:11
Weekly Report: what happened at NCNA last week (0525-0529)?
Weekly Report · 06/01 10:00
Weekly Report: what happened at NCNA last week (0518-0522)?
Weekly Report · 05/25 10:02
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.